Franck Morin

7.7k total citations · 1 hit paper
145 papers, 2.2k citations indexed

About

Franck Morin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Electrical and Electronic Engineering. According to data from OpenAlex, Franck Morin has authored 145 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pulmonary and Respiratory Medicine, 69 papers in Oncology and 19 papers in Electrical and Electronic Engineering. Recurrent topics in Franck Morin's work include Lung Cancer Treatments and Mutations (64 papers), Lung Cancer Diagnosis and Treatment (32 papers) and Lung Cancer Research Studies (32 papers). Franck Morin is often cited by papers focused on Lung Cancer Treatments and Mutations (64 papers), Lung Cancer Diagnosis and Treatment (32 papers) and Lung Cancer Research Studies (32 papers). Franck Morin collaborates with scholars based in France, United States and Switzerland. Franck Morin's co-authors include Gérard Zalcman, B. Milleron, Pierre-Jean Souquet, S. Couraud, Marc Hanna, Patrick Georges, Denis Moro‐Sibilot, Frédéric Druon, Virginie Westeel and Julien Mazières and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Franck Morin

137 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung cancer in never smokers – A review

2012 595 citations S. Couraud, Gérard Zalcman et al. profile →

Peers

Countries citing papers authored by Franck Morin

Since Specialization

Citations

This map shows the geographic impact of Franck Morin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Morin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Morin more than expected).

Fields of papers citing papers by Franck Morin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck Morin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Morin. The network helps show where Franck Morin may publish in the future.

Co-authorship network of co-authors of Franck Morin

This figure shows the co-authorship network connecting the top 25 collaborators of Franck Morin. A scholar is included among the top collaborators of Franck Morin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Morin. Franck Morin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	239MO: Stratification of pleural mesothelioma patients for combined immunotherapy based on sarcomatoid component and tumour microenvironment markers in the IFCT-MAPS2 study 2025 ·Journal of Thoracic Oncology ·Giovanna Tosato, Yuna Blum, (unknown), (unknown), Alexandra Langlais, (unknown), (unknown), (unknown), Clément Meiller, Marie‐Claude Jaurand, Aurélien de Reyniès, V. Westeel, J. Mazieres, (unknown), Franck Morin, Sylvie Lantuéjoul, Arnaud Scherpereel, (unknown), (unknown)	1
2	MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial 2025 ·Translational Oncology ·Guénaëlle Levallet, Christian Créveuil, (unknown), Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuéjoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, Isabelle Monnet, Franck Morin, V. Gounant, Gérard Zalcman	1
3	Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study 2024 ·ESMO Open ·(unknown), Florian Guisier, (unknown), (unknown), (unknown), Pernelle Lavaud, Laurent Greillier, Angélica Tiotiu, Anne Madroszyk, Olivier Bylicki, (unknown), L. Belmont, M. Zysman, (unknown), (unknown), (unknown), Coriolan Lebreton, Franck Morin, (unknown)	2
4	An Experimental Study of an Autonomous Heat Removal System Based on an Organic Rankine Cycle for an Advanced Nuclear Power Plant 2024 ·Energies ·Nicolas Tauveron, (unknown), (unknown), Nadia Caney, Franck Morin	2
5	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project 2020 ·Lung Cancer ·Hélène Blons, (unknown), Jean‐Philippe Merlio, D. Debieuvre, Florence de Fraipont, Clarisse Audigier-Valette, Fabienne Escande, S. Hominal, (unknown), (unknown), L’Houcine Ouafik, Denis Moro‐Sibilot, Antoinette Lemoine, Alexandra Langlais, (unknown), Franck Morin, P.-J. Souquet, Fabrice Barlési, Jacques Cadranel, Michèle Beau‐Faller	7
6	First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial 2020 ·European Respiratory Journal ·A. Lavolé, Laurent Greillier, Julien Mazières, I. Monnet, (unknown), Xavier Quantin, Jean Philippe Spano, H. Léna, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alexandra Langlais, Franck Morin, Alain Makinson, Jacques Cadranel	7
7	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial 2019 ·Clinical Cancer Research ·Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, F. Rivière, I. Monnet, V. Gounant, Henri Janicot, Radj Gervais, (unknown), (unknown), Franck Morin, Gérard Zalcman, Virginie Westeel	15
8	Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project 2019 ·Lung Cancer ·Michèle Beau‐Faller, Erwan Pencreach, Charlotte Leduc, Hélène Blons, Jean‐Philippe Merlio, Pierre‐Paul Bringuier, Florence de Fraipont, Fabienne Escande, Antoinette Lemoine, L’Houcine Ouafik, Marc G. Denis, Paul Hofman, Roger Lacave, Samia Melaabi, Alexandra Langlais, Pascale Missy, Franck Morin, Denis Moro‐Sibilot, Fabrice Barlési, J. Cadranel	13
9	Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO 2018 ·Revue des Maladies Respiratoires ·(unknown), Martine Antoine, Denis Moro‐Sibilot, C. Dayen, B. Mennecier, R. Gervais, Elodie Amour, B. Milleron, Franck Morin, Gérard Zalcman, Marie Wislez	11
10	Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial 2017 ·Annals of Oncology ·Gérard Zalcman, Julien Mazières, Laurent Greillier, (unknown), (unknown), Olivier Bylicki, I. Monnet, R. Corre, Clarisse Audigier-Valette, M. Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, T. Urban, David Planchard, Catherine Ligeza‐Poisson, Elodie Amour, Franck Morin, Denis Moro‐Sibilot, Arnaud Scherpereel	12
11	Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients 2017 ·ESMO Open ·Anastassia Negrouk, Denis Lacombe, Fátima Cardoso, Franck Morin, Eva Carrasco, Joan Maurel, Rudolf Maibach, Enrique Aranda, Richard Marais, Rolf A. Stahel	9
12	Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT) 2017 ·Annals of Oncology ·Charlotte Leduc, Erwan Pencreach, J.P. Merlio, (unknown), Florence de Fraipont, Fabienne Escande, (unknown), (unknown), Hélène Blons, Marc G. Denis, Paul Hofman, Roger Lacave, Samia Melaabi, Alexandra Langlais, (unknown), Franck Morin, Fabrice Barlési, Denis Moro‐Sibilot, J. Cadranel, Michèle Beau‐Faller	0
13	Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) 2016 ·Annals of Oncology ·Charlotte Leduc, Hélène Blons, Benjamin Besse, J.P. Merlio, D. Debieuvre, Antoinette Lemoine, I. Monnet, Damien Pouessel, P. P. Bringuier, M. Poudenx, Isabelle Rouquette, F. Vaylet, Franck Morin, Alexandra Langlais, Élisabeth Quoix, Gérard Zalcman, Denis Moro‐Sibilot, J. Cadranel, Michèle Beau‐Faller, Fabrice Barlési	2
14	Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study) 2015 ·Lung Cancer ·Denis Moro‐Sibilot, Clarisse Audigier-Valette, P. Merle, Élisabeth Quoix, Pierre-Jean Souquet, Fabrice Barlési, C. Chouaïd, Olivier Molinier, Jaafar Bennouna, A. Lavolé, Julien Mazières, Anne‐Claire Toffart, Alexandra Langlais, Franck Morin, Gérard Zalcman	8
15	No impact of passive smoke on the somatic profile of lung cancers in never-smokers 2015 ·European Respiratory Journal ·S. Couraud, D. Debieuvre, L. Moreau, Patrick Dumont, J. Margery, Élisabeth Quoix, Bernard Duvert, L. Cellerin, Nathalie Baize, (unknown), (unknown), Jacques Cadranel, Pascale Missy, Franck Morin, Jean‐François Mornex, Gérard Zalcman, Pierre-Jean Souquet	19
16	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial 2012 ·Clinical Cancer Research ·Florence de Fraipont, Guénaëlle Levallet, Christian Créveuil, Emmanuel Bergot, Michèle Beau‐Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie‐Christine Favrot, D. Debieuvre, Denis Braun, Virginie Westeel, Élisabeth Quoix, Élisabeth Brambilla, Pierre Hainaut, Denis Moro‐Sibilot, Franck Morin, B. Milleron, Gérard Zalcman	46
17	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway 2012 ·Molecular Cancer Therapeutics ·Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, Christian Créveuil, Adriana O. Santos, (unknown), Florence de Fraipont, Élisabeth Brambilla, Jérôme Levallet, Franck Morin, Virginie Westeel, Marie Wislez, Élisabeth Quoix, D. Debieuvre, Fatéméh Dubois, Isabelle Rouquette, Jean-Louis Pujol, Denis Moro‐Sibilot, Jacques Camonis, Gérard Zalcman	74
18	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 2011 ·European Respiratory Journal ·Isabelle Borget, Jacques Cadranel, Jean‐Pierre Pignon, Élisabeth Quoix, Bruno Coudert, Virginie Westeel, Éric Dansin, J. Madelaine, Anne Madroszyk, S. Friard, Catherine Daniel, Franck Morin, C. Chouaïd, (unknown)	27
19	Microjoule femtosecond fiber laser at 16 μm for corneal surgery applications 2009 ·Optics Letters ·Franck Morin, Frédéric Druon, Marc Hanna, Patrick Georges	90
20	C3-04: Phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy (CT) with two different CT regimens in resectable stage I-II non-small cell lung cancer (NSCLC): the IFCT 0002 protocol 2007 ·Journal of Thoracic Oncology ·A Depierre, B. Milleron, Élisabeth Quoix, Marc Puyraveau, Denis Braun, Jean-Luc Breton, L. Bigay-Gamé, Jean-Louis Pujol, Franck Morin, Virginie Westeel	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact